Azacitidine treatment of patient with acute myeloid leukemia secondary to myelofibrosis

Abstract

The treatment of acute myeloid leukemia (AML) is still a medical dilemma, especially in patients with high comorbidities score. Demethylating agents may be the therapeutic option in AML patients under 60-years-old with non-proliferating diseases and high comorbidity index. In this article we presented the case of 57-years-old patient with high-risk secondary to myelofibrosis AML and high comorbidity index, who was treated with azacitidine.